1. Home
  2. ATNM
  3. ATNM News

Latest Actinium Pharmaceuticals Inc. (Delaware) (ATNM) News on August 1, 2025

Actinium Highlights Expanded Data Set for ATNM-400 in Prostate Cancer Demonstrating Superior Efficacy to Enzalutamide and Ability to Overcome Resistance to ARPI Therapy and PSMA-Ac-225/Lu-177 Labelled Radiotherapy at the Society of Nuclear Medicine & Molecular Imaging Annual Meeting
ATNM

PR Newswire

a month ago

Actinium Highlights Expanded Data Set for ATNM-400 in Prostate Cancer Demonstrating Superior Efficacy to Enzalutamide and Ability to Overcome Resistance to ARPI Therapy and PSMA-Ac-225/Lu-177 Labelled Radiotherapy at the Society of Nuclear Medicine & Molecular Imaging Annual Meeting

Life Sciences Investor Forum: Now Available for Online Viewing
ATNM

GlobeNewswire

2 months ago

Life Sciences Investor Forum: Now Available for Online Viewing

Life Sciences Investor Forum Agenda Announced for June 11th-12th
ATNM

GlobeNewswire

2 months ago

Life Sciences Investor Forum Agenda Announced for June 11th-12th

ATNM

Associated Press Finance

3 months ago

Actinium: Q1 Earnings Snapshot

Actinium Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of Texas Southwestern Medical Center
ATNM

PR Newswire

3 months ago

Actinium Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of Texas Southwestern Medical Center

Actinium Presents Data Showing ATNM-400 is More Efficacious than Pluvicto and is Highly Efficacious after Pluvicto Resistance in Prostate Cancer Tumor Models at the American Association for Cancer Research Annual Meeting
ATNM

PR Newswire

3 months ago

Actinium Presents Data Showing ATNM-400 is More Efficacious than Pluvicto and is Highly Efficacious after Pluvicto Resistance in Prostate Cancer Tumor Models at the American Association for Cancer Research Annual Meeting

Actinium Highlights Mutation Agnostic Antileukemic Activity of Actimab-A Against FLT3, NPM1, KMT2A and TP53 Mutations in AML Models Demonstrating Backbone Potential for Acute Myeloid Leukemia Treatment at the American Association for Cancer Research Annual Meeting
ATNM

PR Newswire

3 months ago

Actinium Highlights Mutation Agnostic Antileukemic Activity of Actimab-A Against FLT3, NPM1, KMT2A and TP53 Mutations in AML Models Demonstrating Backbone Potential for Acute Myeloid Leukemia Treatment at the American Association for Cancer Research Annual Meeting

Actinium Pharmaceuticals Announces ATNM-400 a Novel Non-PSMA Targeting First in Class Prostate Cancer Radiotherapy Leveraging Actinium-225
ATNM

PR Newswire

4 months ago

Actinium Pharmaceuticals Announces ATNM-400 a Novel Non-PSMA Targeting First in Class Prostate Cancer Radiotherapy Leveraging Actinium-225

Actinium Pharmaceuticals Provides Business Update After Presentation at Trump Mar-A-Lago Club Announcing Novel Non-PSMA Prostate Cancer Radiotherapy ATNM-400 and Outlining Revitalized Clinical Pipeline with 2025 Corporate Objectives
ATNM

PR Newswire

4 months ago

Actinium Pharmaceuticals Provides Business Update After Presentation at Trump Mar-A-Lago Club Announcing Novel Non-PSMA Prostate Cancer Radiotherapy ATNM-400 and Outlining Revitalized Clinical Pipeline with 2025 Corporate Objectives

Actinium Pharmaceuticals to Host KOL Investor Call at 8am ET Today to Highlight Revamped Clinical Programs and Expanded Market Opportunities Including Newly Initiated Actimab-A Solid Tumor Program
ATNM

PR Newswire

4 months ago

Actinium Pharmaceuticals to Host KOL Investor Call at 8am ET Today to Highlight Revamped Clinical Programs and Expanded Market Opportunities Including Newly Initiated Actimab-A Solid Tumor Program

ATNM

MT Newswires

4 months ago

Actinium Pharmaceuticals Signs Actinium-225 Supply Deal With Eckert & Ziegler

Actinium Pharmaceuticals Announces Supply Agreement with Eckert & Ziegler for Ac-225 Radioisotope to Support Comprehensive Development Activities
ATNM

PR Newswire

4 months ago

Actinium Pharmaceuticals Announces Supply Agreement with Eckert & Ziegler for Ac-225 Radioisotope to Support Comprehensive Development Activities

Actinium Pharmaceuticals Announces Research Collaboration with Memorial Sloan Kettering to Support Further Clinical Expansion of Actimab-A's Backbone Therapy Strategy
ATNM

PR Newswire

4 months ago

Actinium Pharmaceuticals Announces Research Collaboration with Memorial Sloan Kettering to Support Further Clinical Expansion of Actimab-A's Backbone Therapy Strategy

Actinium Pharmaceuticals to Host Investor KOL Call with Dr. Ehab Atallah of the Medical College of Wisconsin and Provide a Pipeline Update Highlighting Revamped Clinical Programs and Expanded Market Opportunities for Actimab-A and Iomab-ACT with Clinical Data in 2H:2025
ATNM

PR Newswire

4 months ago

Actinium Pharmaceuticals to Host Investor KOL Call with Dr. Ehab Atallah of the Medical College of Wisconsin and Provide a Pipeline Update Highlighting Revamped Clinical Programs and Expanded Market Opportunities for Actimab-A and Iomab-ACT with Clinical Data in 2H:2025

Actinium Pharmaceuticals launches clinical trial for Actimab-A in combination
ATNM

TipRanks

4 months ago

Actinium Pharmaceuticals launches clinical trial for Actimab-A in combination

ATNM

MT Newswires

4 months ago

Actinium Pharmaceuticals Launches Clinical Program to Evaluate Actimab-A as Combination Cancer Therapy

Actinium Pharmaceuticals Announces Clinical Trial Program in Solid Tumors Combining Actimab-A with PD-1 Checkpoint Inhibitors KEYTRUDA® and OPDIVO®
ATNM

PR Newswire

4 months ago

Actinium Pharmaceuticals Announces Clinical Trial Program in Solid Tumors Combining Actimab-A with PD-1 Checkpoint Inhibitors KEYTRUDA® and OPDIVO®

Actinium Pharmaceuticals Announces Publication of Actimab-A + CLAG-M Trial Results in Patients with Relapsed or Refractory Acute Myeloid Leukemia in the Peer-Reviewed Journal Leukemia
ATNM

PR Newswire

4 months ago

Actinium Pharmaceuticals Announces Publication of Actimab-A + CLAG-M Trial Results in Patients with Relapsed or Refractory Acute Myeloid Leukemia in the Peer-Reviewed Journal Leukemia

Actinium Pharmaceuticals to Participate at the 37th Annual Roth Conference
ATNM

PR Newswire

5 months ago

Actinium Pharmaceuticals to Participate at the 37th Annual Roth Conference

Actinium Pharmaceuticals Announces Initiation of Actimab-A Triplet Combination Frontline Trial Under NCI CRADA with Venetoclax and Taiho Oncology's Hypomethylating Agent ASTX-727 in Patients with Newly Diagnosed AML
ATNM

PR Newswire

5 months ago

Actinium Pharmaceuticals Announces Initiation of Actimab-A Triplet Combination Frontline Trial Under NCI CRADA with Venetoclax and Taiho Oncology's Hypomethylating Agent ASTX-727 in Patients with Newly Diagnosed AML

Actinium Pharmaceuticals Highlights Antibody Radiation Conjugate Program Developments and Reports Financial Results for the Third Quarter 2024
ATNM

PR Newswire

8 months ago

Actinium Pharmaceuticals Highlights Antibody Radiation Conjugate Program Developments and Reports Financial Results for the Third Quarter 2024

ATNM

Associated Press Finance

9 months ago

Actinium: Q3 Earnings Snapshot

Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors
ATNM

PR Newswire

9 months ago

Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors

All You Need to Know About Actinium (ATNM) Rating Upgrade to Strong Buy
ATNM

Zacks

9 months ago

All You Need to Know About Actinium (ATNM) Rating Upgrade to Strong Buy

Actinium Pharmaceuticals reports data from Phase III trial of AML treatment
ATNM

Clinical Trials Arena

10 months ago

Actinium Pharmaceuticals reports data from Phase III trial of AML treatment

Actinium Pharmaceuticals Announces Publication of Results from the Phase 3 SIERRA Trial of Iomab-B in the Journal of Clinical Oncology
ATNM

PR Newswire

10 months ago

Actinium Pharmaceuticals Announces Publication of Results from the Phase 3 SIERRA Trial of Iomab-B in the Journal of Clinical Oncology

ATNM

MT Newswires

a year ago

B. Riley Downgrades Actinium Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $2 From $16

ATNM

Associated Press Finance

a year ago

Actinium: Q2 Earnings Snapshot

ATNM

MT Newswires

a year ago

Sector Update: Health Care Stocks Fall in Afternoon Trading

ATNM

MT Newswires

a year ago

Sector Update: Health Care Stocks Lean Lower Premarket Monday

ATNM

MT Newswires

a year ago

Sector Update: Health Care

ATNM

MT Newswires

a year ago

Actinium Pharmaceuticals Shares Plunge After FDA Says Iomab-B Trial Does Not Support Planned BLA Filing

ATNM

MT Newswires

a year ago

Top Premarket Decliners

Actinium Provides Regulatory Update on Planned BLA Filing and Future Plans for Iomab-B in the U.S.
ATNM

PR Newswire

a year ago

Actinium Provides Regulatory Update on Planned BLA Filing and Future Plans for Iomab-B in the U.S.

Actinium Expands Patent Coverage Over Iomab-ACT, its Next-Generation Targeted Radiotherapy Conditioning Agent, for Gene Edited Stem Cell-Based Therapies for Non-Malignant Indications
ATNM

PR Newswire

a year ago

Actinium Expands Patent Coverage Over Iomab-ACT, its Next-Generation Targeted Radiotherapy Conditioning Agent, for Gene Edited Stem Cell-Based Therapies for Non-Malignant Indications

ATNM

MT Newswires

a year ago

Actinium Pharmaceuticals Gets FDA Approval for Sickle Cell Disease Treatment Study

Actinium Announces FDA Clearance of Iomab-ACT Targeted Conditioning IND Application for Sickle Cell Disease Patients Undergoing Bone Marrow Transplant in Collaboration with Columbia University
ATNM

PR Newswire

a year ago

Actinium Announces FDA Clearance of Iomab-ACT Targeted Conditioning IND Application for Sickle Cell Disease Patients Undergoing Bone Marrow Transplant in Collaboration with Columbia University

Actinium Pharmaceuticals to Present at the 3rd Annual Targeted Radiopharmaceuticals Summit US
ATNM

PR Newswire

a year ago

Actinium Pharmaceuticals to Present at the 3rd Annual Targeted Radiopharmaceuticals Summit US

Is Actinium Pharmaceuticals (ATNM) Outperforming Other Medical Stocks This Year?
ATNM

Zacks

a year ago

Is Actinium Pharmaceuticals (ATNM) Outperforming Other Medical Stocks This Year?

Treatment of Blood Cancers - Biopharma Companies Building out their Pipeline of Solutions
ATNM

Newsfile

a year ago

Treatment of Blood Cancers - Biopharma Companies Building out their Pipeline of Solutions

Biopharma Stocks Quest for Solutions for Acute Myeloid Leukemia (AML)
ATNM

Newsfile

a year ago

Biopharma Stocks Quest for Solutions for Acute Myeloid Leukemia (AML)

Actinium Presents First Ever Data Demonstrating Actimab-A in Combination with Leading Menin Inhibitors Leads to Anti-Tumor Control and Potent Leukemic Cell Killing in Preclinical Acute Myeloid Leukemia Models at the 2024 EHA Congress
ATNM

PR Newswire

a year ago

Actinium Presents First Ever Data Demonstrating Actimab-A in Combination with Leading Menin Inhibitors Leads to Anti-Tumor Control and Potent Leukemic Cell Killing in Preclinical Acute Myeloid Leukemia Models at the 2024 EHA Congress

Actinium Highlights Oral Presentation at EHA 2024 Annual Congress Featuring Improved Outcomes in TP53 Positive Patients Receiving Iomab-B in the Phase 3 SIERRA Trial
ATNM

PR Newswire

a year ago

Actinium Highlights Oral Presentation at EHA 2024 Annual Congress Featuring Improved Outcomes in TP53 Positive Patients Receiving Iomab-B in the Phase 3 SIERRA Trial

Actinium Announces Results of Actimab-A + CLAG-M Combination Trial Highlighted in Oral Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting
ATNM

PR Newswire

a year ago

Actinium Announces Results of Actimab-A + CLAG-M Combination Trial Highlighted in Oral Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting

Actinium Highlights Mutation Data from the Phase 3 SIERRA Trial of Iomab-B and Novel Linker Technology to Support Solid Tumor Antibody Radiation Conjugate Development at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting
ATNM

PR Newswire

a year ago

Actinium Highlights Mutation Data from the Phase 3 SIERRA Trial of Iomab-B and Novel Linker Technology to Support Solid Tumor Antibody Radiation Conjugate Development at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting

Is Affimed (AFMD) Outperforming Other Medical Stocks This Year?
ATNM

Zacks

a year ago

Is Affimed (AFMD) Outperforming Other Medical Stocks This Year?

Actinium to Host KOL Webinar to Discuss Iomab-ACT Commercial CAR T-Cell Therapy Trial Design, Objectives and Potential Market Opportunity
ATNM

PR Newswire

a year ago

Actinium to Host KOL Webinar to Discuss Iomab-ACT Commercial CAR T-Cell Therapy Trial Design, Objectives and Potential Market Opportunity

Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in TP53 Positive Patients at the EHA 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Receiving an Iomab-B Led Bone Marrow Transplant in the Phase 3 SIERRA Trial
ATNM

PR Newswire

a year ago

Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in TP53 Positive Patients at the EHA 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Receiving an Iomab-B Led Bone Marrow Transplant in the Phase 3 SIERRA Trial

ATNM

MT Newswires

a year ago

Stephens Initiates Actinium Pharmaceuticals With Overweight Rating, $25 Price Target

Actinium Announces Multiple Abstracts Highlighting its Antibody Radiation Conjugates Iomab-B and Actimab-A and Novel Linker Technology for Solid Tumors Accepted for Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting
ATNM

PR Newswire

a year ago

Actinium Announces Multiple Abstracts Highlighting its Antibody Radiation Conjugates Iomab-B and Actimab-A and Novel Linker Technology for Solid Tumors Accepted for Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting

Actinium Announces KOL Webinar to Highlight Recently Announced Iomab-ACT Trial with Leading FDA Approved Commercial CAR T-Cell Therapy Being Led by the University of Texas Southwestern
ATNM

PR Newswire

a year ago

Actinium Announces KOL Webinar to Highlight Recently Announced Iomab-ACT Trial with Leading FDA Approved Commercial CAR T-Cell Therapy Being Led by the University of Texas Southwestern

Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting
ATNM

PR Newswire

a year ago

Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting

Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation at the 50th European Bone Marrow Transplant Annual Meeting
ATNM

PR Newswire

a year ago

Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation at the 50th European Bone Marrow Transplant Annual Meeting

Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy
ATNM

PR Newswire

a year ago

Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy

Actinium Pharmaceuticals Launches Actinium-225 Focused Strategic Initiative to Leverage Proprietary Cyclotron Based Manufacturing Technology to Address Growing Market Demand
ATNM

PR Newswire

a year ago

Actinium Pharmaceuticals Launches Actinium-225 Focused Strategic Initiative to Leverage Proprietary Cyclotron Based Manufacturing Technology to Address Growing Market Demand

Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®
ATNM

PR Newswire

a year ago

Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®

7 Biotech Penny Stocks on the Verge of Clinical Trial Victory
ATNM

InvestorPlace

a year ago

7 Biotech Penny Stocks on the Verge of Clinical Trial Victory

Actinium Highlights Improved Survival with Iomab-B in TP53 Positive Relapsed Refractory Acute Myeloid Leukemia Patients in the SIERRA Trial and Other Presentations at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®
ATNM

PR Newswire

a year ago

Actinium Highlights Improved Survival with Iomab-B in TP53 Positive Relapsed Refractory Acute Myeloid Leukemia Patients in the SIERRA Trial and Other Presentations at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®

NEUBERGER BERMAN HIGH YIELD STRATEGIES FUND ANNOUNCES MONTHLY DISTRIBUTION
ATNM

PR Newswire

2 years ago

NEUBERGER BERMAN HIGH YIELD STRATEGIES FUND ANNOUNCES MONTHLY DISTRIBUTION

ATNM

Business Wire

2 years ago

Templeton Emerging Markets Income Fund ("TEI" or the "Fund") Announces Notification of Sources of Distributions

ATNM

GlobeNewswire

2 years ago

Southern California Bancorp and California BanCorp Announce a Merger of Equals to Create a Premier California Business Bank

ATNM

Thomson Reuters StreetEvents

2 years ago

Q4 2023 First Internet Bancorp Earnings Call

SOPHiA GENETICS Supports Genetic Testing in Brazil
ATNM

PR Newswire

2 years ago

SOPHiA GENETICS Supports Genetic Testing in Brazil

Lantronix Appoints Christa Steele to Its Board of Directors
ATNM

GlobeNewswire

2 years ago

Lantronix Appoints Christa Steele to Its Board of Directors

First Internet (INBK) Reports Q4 Earnings: What Key Metrics Have to Say
ATNM

Zacks

2 years ago

First Internet (INBK) Reports Q4 Earnings: What Key Metrics Have to Say

First Internet Bancorp (INBK) Q4 Earnings and Revenues Surpass Estimates
ATNM

Zacks

2 years ago

First Internet Bancorp (INBK) Q4 Earnings and Revenues Surpass Estimates

First Internet Bancorp (INBK) Reports Solid Q4 and Full Year 2023 Earnings Growth
ATNM

GuruFocus.com

2 years ago

First Internet Bancorp (INBK) Reports Solid Q4 and Full Year 2023 Earnings Growth

CONSOL Energy (CEIX) Returned 61% Despite 25% Fall in Estimates
ATNM

Insider Monkey

2 years ago

CONSOL Energy (CEIX) Returned 61% Despite 25% Fall in Estimates

Here’s Why Saga Communications (SGA) Increased in Q4
ATNM

Insider Monkey

2 years ago

Here’s Why Saga Communications (SGA) Increased in Q4

DLH to Announce Fiscal 2024 First Quarter Financial Results
ATNM

GlobeNewswire

2 years ago

DLH to Announce Fiscal 2024 First Quarter Financial Results

At US$16.29, Is DLH Holdings Corp. (NASDAQ:DLHC) Worth Looking At Closely?
ATNM

Simply Wall St.

2 years ago

At US$16.29, Is DLH Holdings Corp. (NASDAQ:DLHC) Worth Looking At Closely?

SOUTHERN CALIFORNIA BANCORP ANNOUNCES THE RETIREMENT OF CHAIRMAN EMERITUS AND DIRECTOR JOHN FARKASH
ATNM

GlobeNewswire

2 years ago

SOUTHERN CALIFORNIA BANCORP ANNOUNCES THE RETIREMENT OF CHAIRMAN EMERITUS AND DIRECTOR JOHN FARKASH

XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition
ATNM

GlobeNewswire

2 years ago

XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition

Office Properties Income Trust Fourth Quarter 2023 Conference Call Scheduled for Friday, February 16th
ATNM

Business Wire

2 years ago

Office Properties Income Trust Fourth Quarter 2023 Conference Call Scheduled for Friday, February 16th

MiX Telematics Sets Third Quarter Fiscal Year 2024 Conference Call for February 1, 2024, at 8:00 a.m. ET and 3:00 p.m. SAST
ATNM

Business Wire

2 years ago

MiX Telematics Sets Third Quarter Fiscal Year 2024 Conference Call for February 1, 2024, at 8:00 a.m. ET and 3:00 p.m. SAST

Annexon (ANNX) Stock Rallies 156% in 3 Months: Here's How
ATNM

Zacks

2 years ago

Annexon (ANNX) Stock Rallies 156% in 3 Months: Here's How

ATNM

Business Wire

2 years ago

Franklin Templeton Closed-End Funds Announce Share Repurchases for the Fourth Quarter of 2023

Office Properties Income Trust Announces 2023 Dividend Allocations
ATNM

Business Wire

2 years ago

Office Properties Income Trust Announces 2023 Dividend Allocations

Sidoti Events, LLC's Virtual January Micro-Cap Conference
ATNM

ACCESSWIRE

2 years ago

Sidoti Events, LLC's Virtual January Micro-Cap Conference

Enhabit (NYSE:EHAB) Has Some Difficulty Using Its Capital Effectively
ATNM

Simply Wall St.

2 years ago

Enhabit (NYSE:EHAB) Has Some Difficulty Using Its Capital Effectively

LuxUrban Hotels Announces that The Royalton by LuxUrban, Trademark Collection® by Wyndham Will Begin Welcoming Guests in January
ATNM

Business Wire

2 years ago

LuxUrban Hotels Announces that The Royalton by LuxUrban, Trademark Collection® by Wyndham Will Begin Welcoming Guests in January

FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx
ATNM

GlobeNewswire

2 years ago

FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx

Mondee to Participate in 26th Annual Needham Growth Conference
ATNM

GlobeNewswire

2 years ago

Mondee to Participate in 26th Annual Needham Growth Conference

Zacks.com featured highlights include JAKKS Pacific, The Andersons, RCM Technologies and Tactile Systems Technology
ATNM

Zacks

2 years ago

Zacks.com featured highlights include JAKKS Pacific, The Andersons, RCM Technologies and Tactile Systems Technology

Merck-Harpoon deal, Twilio, Crocs: Trending Tickers
ATNM

Yahoo Finance Video

2 years ago

Merck-Harpoon deal, Twilio, Crocs: Trending Tickers

ATNM

Business Wire

2 years ago

Templeton Emerging Markets Income Fund ("TEI" or the "Fund") Announces Distribution

Is DLH Holdings Corp. (DLHC) Stock Priced for the “Worst Case” Scenario?
ATNM

Insider Monkey

2 years ago

Is DLH Holdings Corp. (DLHC) Stock Priced for the “Worst Case” Scenario?

Resources Connection Inc (RGP) Faces Revenue Decline Amid Economic Challenges in Q2 Fiscal 2024
ATNM

GuruFocus.com

2 years ago

Resources Connection Inc (RGP) Faces Revenue Decline Amid Economic Challenges in Q2 Fiscal 2024

Voyager (VYGR) Gains on Gene Therapy Deal With Novartis
ATNM

Zacks

2 years ago

Voyager (VYGR) Gains on Gene Therapy Deal With Novartis

PIMCO Closed-End Funds Declare Monthly Common Share Distributions
ATNM

GlobeNewswire

2 years ago

PIMCO Closed-End Funds Declare Monthly Common Share Distributions

HF Foods To Participate in the 2024 ICR Conference
ATNM

GlobeNewswire

2 years ago

HF Foods To Participate in the 2024 ICR Conference

Actinium Announces Acceptance of Five Abstracts for Presentation at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®
ATNM

PR Newswire

2 years ago

Actinium Announces Acceptance of Five Abstracts for Presentation at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®

ATNM

Business Wire

2 years ago

FREYR Battery Completes Redomicile from Luxembourg to the U.S.

HF Foods Group (NASDAQ:HFFG) investors are sitting on a loss of 59% if they invested five years ago
ATNM

Simply Wall St.

2 years ago

HF Foods Group (NASDAQ:HFFG) investors are sitting on a loss of 59% if they invested five years ago

Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023
ATNM

GlobeNewswire

2 years ago

Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023

Forge Bolsters Roster with Strategic Hires to Deliver Greater Value to Private Company Partners, Institutional Investors
ATNM

Business Wire

2 years ago

Forge Bolsters Roster with Strategic Hires to Deliver Greater Value to Private Company Partners, Institutional Investors

11 Most Promising Psychedelic Stocks According to Hedge Funds
ATNM

Insider Monkey

2 years ago

11 Most Promising Psychedelic Stocks According to Hedge Funds

Alpha Tau to Present at the 42nd Annual J.P. Morgan Healthcare Conference
ATNM

GlobeNewswire

2 years ago

Alpha Tau to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Heritage Announces Closing of Primary Public Offering of Shares of Common Stock and Concurrent Private Placement
ATNM

PR Newswire

2 years ago

Heritage Announces Closing of Primary Public Offering of Shares of Common Stock and Concurrent Private Placement

ATNM

Business Wire

2 years ago

Templeton Emerging Markets Income Fund ("TEI") Announces Change to Managed Distribution Plan

Share on Social Networks: